

5<sup>th</sup> Tropé - Kolstad meeting

# UPDATES IN GYNECOLOGIC ONCOLOGY

Friday December 5, 2014 - 09:00 - 18:00



Sponsored by

**INGER AND JOHN FREDRIKSEN FOUNDATION FOR  
OVARIAN CANCER RESEARCH**

The meeting takes place in the Auditorium of Building K, Institute for Cancer Research  
Oslo University Hospital, The Norwegian Radium Hospital, Oslo, Norway

# SCIENTIFIC PROGRAM

## DECEMBER 5, 2014

09:00 – 09:05    **Welcome**  
*Dr. Erik Røkkones, MD, PhD, Chairman of the Department of  
Gynaecological Oncology, the Norwegian Radium Hospital (Norway)*

### **Molecular Characteristics of Ovarian Cancer**

Chair: *Dr. Anne Dørum, MD, PhD (Norway)*

09:05 – 09:35    **Chemoresistance Markers in Metastatic Ovarian Carcinoma**  
*Prof. Ben Davidson, MD, PhD (Norway)*

09:35 – 09:40    Discussion

09:40 – 10:10    **Molecular Predictor of Residuals in Patients with Ovarian Cancer**  
*Professor Beth Karlan, MD (USA)*

10:10 – 10:15    Discussion

10:15 – 10:45    **Impact of Oophorectomy on Cancer Incidence and Mortality in  
Women with BRCA1 or BRCA2 Mutation**  
*Prof. Pål Møller, MD, PhD (Norway)*

10:45 – 10:50    Discussion

10:50 – 11:20    *Coffee break*

11:20 – 11:50    **Does Overlap in Molecular and Histologic Subtypes Support New  
Strategies for Clinical Trials?**  
*Prof. Helga Salvesen, MD, PhD (Norway)*

11:50 – 12:00    Discussion

### **The 5<sup>th</sup> Tropé-Kolstad Lecture**

Introduction: *Dr. M Bilal Sert, MD (Norway)*

12:00 – 13:00    **Epithelial Ovarian Cancer: A Real Challenge for the Next 25 Years!  
The Surgeon's Viewpoints**  
*Prof. Neville Hacker, MD (Australia)*

13:00 – 14:00    *Lunch*

### **Controversies in Ovarian Cancer Treatment**

Chair: *Dr. Tone Skeie-Jensen, MD, PhD (Norway)*

14:00 – 14:40    **Neoadjuvant Chemotherapy in Ovarian Cancer**  
*Pro: Professor Beth Karlan, MD (USA)*  
*Con: Prof. Neville Hacker, MD (Australia)*

- 14:40 – 14:45 Discussion
- 14:45 – 15:05 **Fluorescent Lymphatic Mapping in Gynecology**  
*Prof. Nadeem Abu-Rustum, MD (USA)*
- 15:05 – 15:20 **Secondary Cytoreduction of Recurrent Ovarian Cancer using Robotic Platform**  
*Dr. Ane Gerda Zahl Eriksson, MD (USA)*
- 15:20 – 15:25 Discussion

### **Ovarian Cancer and Pregnancy**

Chair: *Dr. Janne Kærn, MD, PhD (Norway)*

- 15:25 – 15:45 **Ovarian Cancer in Pregnancy**  
*Prof. Frédéric Amant, MD, PhD (Belgium)*
- 15:45 – 15:50 Discussion

### **Germinal Cell Tumors of the Ovary**

Chair: *Prof. Vera Abeler, MD, PhD (Norway)*

- 15:50 – 16:10 **Post-Treatment Fertility and Gonadal Function in Young Women Diagnosed with a Malignant Ovarian Germ Cell Tumor (MOGCT) During the “Cisplatin Era”**  
*Dr. Olesya Solheim, MD (Norway)*
- 16:10 – 16:15 Discussion

### **Prospective Clinical Studies in Advanced Ovarian Cancer**

Chair: *Prof. Bjørn Hagen, MD, PhD (Norway), Dr. Brynhildur Eyjólfsdóttir (Norway)*

- 16:15 – 16:45 **Updates of the Prospective Randomized Studies in Advanced Epithelial Ovarian Cancer in the World Today**  
*Professor Gunnar B Kristensen, MD, PhD (Norway)*
- 16:45 – 16:55 Discussion
- 16:55 – 17:25 **Coffee break**
- 17:25 – 17:45 **Summary of the 2014 MD Andersson International Meeting in Ovarian Cancer: Emerging Therapies in Ovarian Cancer**  
*Prof. Nadeem Abu-Rustum, MD (USA)*
- 17:45 – 17:55 Discussion
- 17:55 – 18:00 **Closing remarks**  
*Professor Beth Karlan, MD (USA)*



## **Professor Ben Davidson, MD, PhD**

Oslo University Hospital, the Norwegian Radium Hospital, Oslo, Norway

**Date and place of birth:** September 23, 1964; Tel Aviv, Israel. **Citizenship:** Israeli

**Present position:** Senior Pathologist and Head of Research, Department of Pathology, Oslo University Hospital; Professor, University of Oslo

### **Education**

2003-2004: Post-doctoral fellow at NCI/NIH, Bethesda MD  
1998-2001: Ph.D. program, Norwegian Radium Hospital; Thesis defended 23/8/01  
1986-1992: Medical studies in Sackler School of Medicine, Tel-Aviv University

### **Brief Chronology of employment**

2002-present: Staff pathologist, Department of Pathology, Norwegian Radium Hospital, Oslo, Norway;  
Sub-specialist in cytopathology and gynecologic pathology  
1998-2002: Resident (combined with PhD program), Department of Pathology, Norwegian Radium Hospital, Oslo, Norway  
1994-1998: Resident, Department of Pathology, Sheba Medical Center, Tel Hashomer, Israel

### **Membership in professional and scientific societies**

1. The American Association for Cancer Research; 2. The International Academy of Pathology (Norwegian division); 3. The European Society of Pathology; 4. The International Society of Gynecological Pathology; 5. Nordic Society of Gynecologic Oncology

### **Scientific appointments**

**2012-:** Editorial board member in *Gynecologic Oncology*  
**2011-:** Associate Editor, *Frontiers in Women's Cancer*  
**2011-:** Editorial board member in *Human Pathology*  
**2010-:** Editorial board member in *Virchows Archiv*  
**2010:** Associate Editor, *Journal of Oncology*, Special issue titled *Molecular Genetic Markers in Female Reproductive Cancers*  
**2006-2013:** Member of the grant application committee, Norwegian Cancer Society  
**2005-2012:** Section Editor in *Diagnostic Cytopathology*

### **Invited speaker and Reviewer**

- Reviewed a large number of manuscripts for leading international peer-reviewed journals, including *Nature Reviews Cancer*, *Lancet Oncology*, *Cancer Research*, *Clinical Cancer Research*, *Molecular Cancer Research*, *Annals of Oncology*, *The American Journal of Pathology*, *Oncogene* and *Cancer*.  
- Invited speaker in 26 sessions in international conferences in 2004-2014

**Publications (excluding abstracts) in peer-reviewed journals:** 257 per November 2014

In addition, Editor of a book on serous effusions with Springer and author of 5 chapters.



**Professor Pål Møller, MD, PhD**

Oslo University Hospital, the Norwegian Radium Hospital, Oslo, Norway

MD, PhD, Senior Consultant, Senior Scientist.

From a background of internal medicine and a PhD on multifactorial inheritance, he was in 1988 asked to erect combined research on and health service for inherited cancer at the Norwegian Radium Hospital – currently a unit within Oslo University Hospital. He joined the international organizations developing the mathematical models to describe inherited cancer, and the inter-professional organizations describing the inherited cancer syndromes, uncover their genetic causes and advocating intervention strategies to prevent and cure. Genetic understanding is based upon genetic epidemiological facts on the inherited diseases in question, to which purpose he together with the organizations mentioned issued standardized guidelines for health care. Implementing these in the Norwegian health care system which covers all Norwegian, the system was made an open observational trial. Together with others having the same intention on providing information based on prospective observations (not only retrospective as close to all information was and still is), he became partner in broad international collaborative prospective studies. To this end he had to keep all relevant information, and in the absence of systems to do so he made his own combined electronic medical filing and research system. Today, information from the thousands of families examined the last 25 years, including results of testing for the known causative genes and effects of interventions over all these years, are available to describe the genetic epidemiology of the inherited cancers and the effects of the interventions undertaken. Because of numbers needed to arrive at conclusions, it is necessary to compile international series from different centres, for which reason the broad international collaborations are continuously ongoing. Inherited ovarian cancer is part of inherited breast-ovarian cancer caused by the BRCA1/2 genes and inherited colorectal cancer (Lynch syndrome) caused by four mismatch-repair genes. Updates from the international collaborative prospective studies on these two inherited cancers syndromes will be given.



**Professor Beth Y. Karlan, MD**

Cedars-Sinai Medical Center, Los Angeles, CA, USA

**Position title**

Director, Women's Cancer Program. Director, Gynecologic Oncology

**Education/training: Institution and location, degree, year(s), field of study**

Harvard-Radcliffe College, Cambridge, MA , B.A., 1978, Biochemistry Sciences

Harvard Medical School, Cambridge, MA, M.D., 1982, Medicine

Yale-New Haven Hospital, New Haven, CT, Residency, 1982-86, Obstetrics & Gynecology

Yale Univ. School of Medicine, New Haven, CT, Research Fellow, 1986-87, Molecular Biology

UCLA School of Medicine, Los Angeles, CA, Clinical Fellow, 1987-89, Gynecologic Oncology

**Personal statement**

As a physician and translational researcher, I have more than 30 years experience treating patients with female reproductive malignancies and investigating pressing clinical questions in the clinic and the laboratory. My research interests include the genetic and phenotypic determinants of human ovarian carcinoma, hereditary predisposition to cancer, and molecular biomarkers for early detection, treatment and prognostication of ovarian cancer. I have been awarded research grants from the Department of Defense, National Institutes of Health and the American Cancer Society. In 1989 I established a human tissue biorepository to collect and preserve fresh frozen tissue, serum, germline DNA from blood and paraffin blocks to be used for translational research studies. As of 2013, the collection contains more than 100,000 unique specimens donated by more than 10,000 patients and correlated with relevant clinical data. This robust and valuable resource has been the backbone of much of my research and will be available for the proposed projects. In addition, in 1990 I initiated the Gilda Radner Hereditary Cancer Detection Program, which enrolls women who undergo BRCA testing due to personal and/or family diagnoses. This work contributed to national ovarian cancer screening guidelines, and we are currently working with international collaborators to identify genetic modifiers of disease penetrance in carriers of deleterious BRCA gene mutations. We have also been working to identify improved biomarkers for early detection, and one of the markers identified from analysis of tumors from our bank is FDA approved and used in clinical practice for detecting recurrent ovarian cancer and triaging a pelvic mass. Throughout my career, I have devoted myself to advancing the specialty of gynecologic oncology through leadership, mentorship, and patient advocacy. I have served as president of our national and local professional societies, testified before congress in support of increased research funding and patient education, contributed to the training of many of my most respected colleagues, and currently serves as editor-in-chief of the journals *Gynecologic Oncology* and *Gynecologic Oncology Case Reports*. *My ongoing efforts are inspired by the women that I treat, and dedicated to improving their lives through discovery and innovation.*

### Positions and Employment

1995-Present	Director, Division of Gynecologic Oncology, Cedars-Sinai Medical Center, Los Angeles, CA
1998-2005	Director, Gynecologic Oncology Fellowship Program, UCLA/Cedars-Sinai Medical Centers, Los Angeles, CA
2001-Present	Professor, Obstetrics and Gynecology, David Geffen School of Medicine at UCLA, Los Angeles, CA
2002-2010	Director, Women's Cancer Research Institute, Cedars-Sinai Medical Center, Los Angeles, CA
2007-Present	Director, Women's Reproductive Cancers, Center of Excellence, Cedars-Sinai Medical Center, Los Angeles, CA
2011-Present	Director, Women's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA

### Other Experience and Professional Memberships

1993	Consultant, Prostate, Lung, Colon & Ovarian Cancer Screening Trial, NCI
1997	Group Leader, Strategic Planning Conference on New Directions in Ovarian Cancer Research, NCI
1999-2005	Board of Governors, American College of Surgeons
2000-2004	Integration Panel for the Ovarian Cancer Research Program, DOD (Chair, 2002-2003)
2000-Present	Scientific and Medical Advisory Committee, Ovarian Cancer National Alliance,
2001-2008	Subspecialty Board Member (Gynecologic Oncology), American Board of Obstetrics & Gynecology
2002-2003	President, Los Angeles Obstetrical and Gynecological Society
2004-2005	President, Western Association of Gynecologic Oncologists
2005-2006	President, Society of Gynecologic Oncologists
2006-2012	Member, Board of Directors, Cedars-Sinai Medical Center
2008-Present	Editor-In-Chief, <i>Gynecologic Oncology</i>
2008-Present	Chair, Scientific Advisory Board Clarity Foundation
2008-Present	Board of Directors, Ovarian Cancer Research Fund
2011-Present	Editor-In-Chief, <i>Gynecologic Oncology Case Reports</i>
2012-Present	Member, Conquer Cancer Foundation
2013-Present	Member, National Cancer Advisory Board

### Honors

1986	ACOG-Ortho Academic Training Fellowship in Obstetrics and Gynecology
1990	American Cancer Society Clinical Oncology Career Development Award
1992	Berlex Foundation Scholar Award
1993	Richard F. Dwyer and Eleanor W. Dwyer Award for Excellence
1995-Present	Board of Governors' Endowed Chair, Gynecologic Oncology, Cedars-Sinai Medical Center
1996	Award for Excellence, Israel Cancer Research Fund
1998	Nat King Cole Research Award, Research for Women's Cancers, Cedars-Sinai Medical Center
2001	Gynecologic Cancer Foundation, Public Service Award
2006-2011	American Cancer Society, Early Detection Professorship
2008	Gynecologic Cancer Foundation/Margaret Greenfield/Carmel Cohen, MD, Excellence in Ovarian Cancer Research Award
2011-2016	American Cancer Society, Clinical Research Professorship

### Scientific publications

Karlan has published more than 230 Peer-Reviewed publications





### **Professor Helga Salvesen, MD, PhD**

University of Bergen, Haukeland University Hospital, Bergen, Norway

Born in Oslo, Norway in 1963.

#### **Education, training and academic appointments:**

**MD**, Un. of Bergen, Norway (1989); **PhD** Un. of Bergen (cancer research) (2000); **Visiting scholar**, Un. of Chicago, USA (1998-99); **Specialist in obstetrics and gynecology**, Norway (EBCOG requirements) (2001); **Consultant in gynecologic oncology**, Haukeland Un. Hospital, Norway (2001); **Professor**, Un. of Bergen (2003); Visiting professor, Harvard University, Dana Farber Cancer Institute, Boston, USA (2004-05); **Visiting professor**, Harvard University, Broad Institute, USA (2012-13).

**Scientific experience:** H1 25, ≈115 PubMed listed original articles. Population based tissue bank for gynecologic malignancies, Un. of Bergen (PI); International prospective multicenter trial MoMaTEC (Molecular Markers in Treatment of Endometrial Cancer (PI).

**Trainees:** 5 (past) and 8 (current) PhD students; 7 postdocs; 3 medical students.

**Invited speaker:** Harvard/DFCI (2006, 2009); Max Planck Institute, Cologne, Germany (2009); 13<sup>th</sup> Biennial Meeting International Gynecologic Cancer Society (IGCS), Prague (2010); 17th Meeting of European Society of Gynaecological Oncology (ESGO), Milan (2011); American Society of Clinical Oncology (ASCO) meeting, Chicago (2011); European Society for Medical Oncology (ESMO) meeting, Stockholm (2011).

**Prizes/awards:** **Best presentation** at the Annual meeting of Norwegian Gynecological society (1996); twice appointed **best teacher**, medical school (preclinical), Un. of Bergen (1997,98); **Superscientists**, Federation of Scandinavian Societies of Obstetrics and Gynecology (1998); **Falchs juniorprice**, Un. of Bergen (2003); **Fulbright Foundation** award for overseas studies, Harvard, Boston, USA (2004); **Publication of the year**, Medical Faculty, Un. of Bergen for PNAS paper (2009); Helse Vest **Innovation prize** (2011).

**Major administrative experiences:** President, Norwegian Forum for Gynecologic Oncology (2003-10); President, Norwegian Oncologic Forum (2007-08); Board member (secretary), Chairman surgery group, Nordic Society for Gynecologic Oncology (2006-10); Assistant Dean, Department of Clinical Medicine, Un. of Bergen (2005-10); Board member FriMed Norwegian Research Council (2005-09); Senior editor, International Journal of Gynecological Cancer (2008-); Council member, European Society for Gynecologic Oncology (ESGO) (2009-); Member of the Uterine task Force NCI/NIH (2010-); Disease working group, The Cancer Genome Atlas (TCGA) for Endometrial Cancer (2010-); Chair, European Network for Individualized Treatment of Endometrial Cancer (ENITEC) (2010-); Member of steering group, European Network for Translational Research in Gynecologic Oncology (ENTRIGO) (2010-).

**Patents/Licensing agreement:** US 12/962,946, covered by license agreement with OvaGene.





### **Professor Neville Hacker, MD**

The University of New South Wales, Australia

Professor Neville Hacker AM graduated with First Class Honours from the University of Queensland in 1967. He trained in Obstetrics and Gynaecology at the Royal Women's Hospital in Brisbane, and went to the University of California, Los Angeles (UCLA) to do a Fellowship in Gynaecological Oncology in 1978. After a 2 year Fellowship, he was appointed to the Faculty and in 1985, he was appointed Director of Gynaecological Oncology at UCLA. In November 1986, he returned to Australia to establish the Gynaecological Cancer Centre at the Royal Hospital for Women. He has been Director of that Centre subsequently, and is a Conjoint Professor of Gynaecological Oncology at the University of New South Wales.

Professor Hacker is a Fellow of the Royal Australian and New Zealand College of Obstetricians and Gynaecologists, a Fellow of the Royal College of Obstetricians and Gynaecologists, a Fellow of the American College of Obstetricians and Gynecologists, and a Fellow of the American College of Surgeons.

He is a past Chairman of the Oncology Committee of the RANZCOG, a Past President of the International Gynecologic Cancer Society, and a Past President of the Society of Pelvic Surgeons. He has received numerous Awards, including the 2007 Wertheim Award, the 2008 IGCS Award, the inaugural Prof Robert Sutherland Award from the NSW Cancer Institute, and the inaugural Jeanne Ferris Award from the Australian Government and Cancer Australia, both in 2013.

He has written over 180 peer-reviewed articles, 44 book chapters, and two books, Hacker and Moore's **Essentials of Obstetrics and Gynecology** and Berek and Hacker's **Gynecologic Oncology**, both in their 5<sup>th</sup> Edition.



**Professor Nadeem R. Abu-Rustum, MD**

Memorial Sloan Kettering Cancer Center, New York, USA

Nadeem R. Abu-Rustum, M.D. is the Chief of the Gynecology Service in the Department of Surgery at Memorial Sloan Kettering Cancer Center in New York.

He is a Professor at Weill Medical College of Cornell University in New York and is the Vice-Chair for Technology Development at Memorial Sloan Kettering Cancer Center.

He completed his Residency in Obstetrics and Gynecology at the Greater Baltimore Medical Center in Baltimore Maryland and a Fellowship in Gynecologic Oncology at Memorial Sloan Kettering Cancer Center.

He has authored or co-authored more than 200 publications and is co-author to numerous book chapters and three textbooks in gynecologic oncology.

He is in full-time practice of gynecologic oncology at Memorial Sloan Kettering Cancer Center in New York.



**Ane Gerda Zahl Eriksson, MD**

Memorial Sloan Kettering Cancer Center, New York, USA

Dr. Eriksson is a Gynecologic Oncology Fellow in the Department of Surgery at Memorial Sloan Kettering Cancer Center.

Dr. Eriksson earned her medical degree from the Medical University of Warsaw, graduating first in her class. As a medical student she developed an early interest in embryology and was awarded a scholarship from the Norwegian Research Council to perform research on malformations of the central nervous system at the National Center for Fetal Diagnostics. This research encouraged her to pursue a residency in Obstetrics and Gynecology. During residency her focus changed from fetal diagnostics to gynecologic oncology, and she completed the final 18 months of residency at the Norwegian Radium Hospital. Dr. Eriksson is currently pursuing specialty training in Gynecologic Oncology at MSKCC.

Dr. Eriksson has throughout her career been devoted to medical education and international collaboration. She is a founding member of the Polish chapter for the Association of Norwegian Students Abroad (ANSA), she has served as President of the Norwegian Medical Student Association, foreign division (NMF), President for the Norwegian Association of Residents in Obstetrics and Gynecology and represented the organization in the European Network of Trainees in Obstetrics and Gynecology (ENTOG). Dr. Eriksson has also served on the Board for the Norwegian Association of Obstetrics and Gynecology.

Her current research centers on minimally invasive surgery in gynecologic oncology and the utilization of sentinel lymph node mapping for uterine cancers. She plans on pursuing an academic career in Gynecologic Oncology upon completion of her fellowship.



**Professor Frédéric Amant, MD, PhD**

UZ Gasthuisberg/KU Leuven, Belgium

Frédéric Amant, MD, PhD (°1967), received his medical degree from the University of Leuven (KU Leuven), Belgium in 1992, completed his specialty training as an obstetrician/gynecologist in 1998, and his subspecialty training in gynecologic oncology in 2000.

He is professor at the KU Leuven, Belgium. He is a specialist in Gynecologic Oncology at the University Hospitals (UZ Gasthuisberg) Leuven and heads the scientific section of this specialty.

Frédéric Amant heads the International Network on 'Cancer, Infertility and Pregnancy' (INCIP) of the European Society of Gynecologic Oncology (ESGO) ([www.cancerinpregnancy.org](http://www.cancerinpregnancy.org)).

He chairs the Endometrium Tumor Site Committee of the European Organization for Research and Treatment of Cancer (EORTC), Gynecologic Cancer Group. He is co-chair of the European Network Individualized Treatment Endometrial Cancer (ENITEC), a task force within the ESGO. He chairs the patient derived tumour xenograft platform (PDTX) at the KU Leuven and is member of the European consortium on xenografts.



**Olesya Solheim, MD, PhD fellow**

Oslo University Hospital, the Norwegian Radium Hospital, Oslo, Norway

MD, PhD fellow at the Department of Gynecological Oncology, the Norwegian Radium Hospital.

Olesya Solheim has her medical education from the State Medical Academy of Arkhangelsk, Russia, 1999. After receiving her degree as medical doctor she underwent 4 years of specialization within obstetrics and gynecology from the same institution.

Dr Solheim moved to Norway in 2003 and received authorization of her medical education from Russia as professionally equivalent to the degree Candidate of Medicine of the University of Oslo (Candidata Medicinae - Cand. Med.). Having settled in Oslo she has been working at different departments of Oslo University hospital. In the period 2006-2007, she was trained in internal medicine at Lillehammer hospital, and was in 2007 authorized as medical doctor by the Norwegian governmental office for authorization of health personnel.

Since 2008 she has been working at the Oslo University Hospital, Dep. Of Gynecological Oncology, the Norwegian Radium Hospital.

From March 2012 Olesya Solheim has been engaged as PhD fellow in the project "Long-term outcome in survivors after Germ Cell Ovarian Cancer". This project is the first national study of Germ Cell ovarian tumors and is conducted in cooperation between the Departments of gynecological oncology in Oslo, Trondheim, Bergen, Tromsø and the National Resource Center for Studies after Treatment for Cancer OUS, the Norwegian Radium Hospital.

**Publications:**

Malignant ovarian germ cell tumors: presentation, survival and second cancer in a population based Norwegian cohort (1953-2009). Solheim O, Kærn J, Tropé CG, Rokkones E, Dahl AA, Nesland JM, Fosså SD. Gynecol Oncol. 2013 Nov;131(2):330-5.

Prognostic factors in malignant ovarian germ cell tumours (The Surveillance, Epidemiology and End Results experience 1978-2010). Solheim O, Gershenson DM, Tropé CG, Rokkones E, Sun CC, Weedon-Fekjaer H, Fosså SD. Eur J Cancer. 2014 Jul;50(11):1942-50.



**Professor Gunnar B Kristensen, MD, PhD**

Oslo University Hospital, the Norwegian Radium Hospital, Oslo, Norway

Born 1946 in Denmark

Medical degree 1972

Specialist in Gynecology and Obstetrics 1972

Senior physician in Oncology 1982

Senior physician in Obstetrics and Gynecology, Denmark 1983-89

Consultant in Gynecologic Oncology, The Norwegian Radium Hospital since 1990

1999 Thesis, Oslo, Norway.

2013 Appointed as professor in Gynecology and Obstetrics at University in Oslo.

President for Nordic Society for Gynecologic Oncology (NSGO) 1999-2006

Director of NSGO-CTU (Clinical Trial Unit) 2006-2013

Authorship of 225 scientific articles published in international, peer-reviewed journals.

Author of chapters in 20 books.

## List of participants

Last name	First name	Affiliation	Country
<b>Abeler</b>	Vera	The Norwegian Radium Hospital	Norway
<b>Abu-Rustum</b>	Nadeem	Memorial Sloan Kettering Cancer Center, New York	USA
<b>Ahlgren</b>	Madelaine	Karlskrona Hospital	Sweden
<b>Ahuja</b>	Vijay K.	Women's Hospital, Doha	Qatar
<b>Amant</b>	Frédéric	UZ Gasthuisberg/KU Leuven	Belgium
<b>Anderssen</b>	Elena	University Hospital of North Norway	Norway
<b>Andersson</b>	Yvonne	The Norwegian Radium Hospital	Norway
<b>Arildsen</b>	Nicolai Skovbjerg	Lund University	Sweden
<b>Auranen</b>	Annika	Turku University Hospital	Finland
<b>Bäckman</b>	Fatma	Örebro University Hospital	Sweden
<b>Bangshøj</b>	Rene	Örebro University Hospital	Sweden
<b>Berle</b>	Einar	Oslo Medical Center	Norway
<b>Bischof</b>	Katharina	Haukeland University Hospital	Norway
<b>Bjørge</b>	Line	Haukeland University Hospital	Norway
<b>Bjørn</b>	Signe Frahm	Rigshospitalet, Copenhagen	Denmark
<b>Blaakær</b>	Jan	Aarhus University Hospital	Denmark
<b>Bondhus</b>	Sissel	Roche Norge	Norway
<b>Bossmar</b>	Thomas	University of Lund	Sweden
<b>Chrisanthar</b>	Ranjan	The Norwegian Radium Hospital	Norway
<b>Dahl</b>	Gunn Fallås	The Norwegian Radium Hospital	Norway
<b>Davidson</b>	Ben	The Norwegian Radium Hospital	Norway
<b>Dørum</b>	Anne	The Norwegian Radium Hospital	Norway
<b>Elgaaen</b>	Bente Vilming	The Norwegian Radium Hospital	Norway
<b>Eroukhmanoff</b>	Lena	NCMM, University of Oslo	Norway
<b>Eraker</b>	Runar	Akershus University Hospital	Norway
<b>Eriksson</b>	Ane Gerda Zahl	Memorial Sloan Kettering Cancer Center, New York	USA
<b>Eyjolfsdottir</b>	Brynhildur	The Norwegian Radium Hospital	Norway
<b>Fiane</b>	Bent	Stavanger University Hospital	Norway
<b>Flaten</b>	Kristine	Drammen Hospital	Norway
<b>Frøding</b>	Ligita P	Rigshospitalet, Copenhagen	Denmark
<b>Hacker</b>	Neville	The University of New South Wales	Australia
<b>Hagen</b>	Bjørn	St. Olavs Hospital	Norway
<b>Hamid</b>	Bushra Hassan	Roskilde Hospital	Denmark
<b>Hansen</b>	Lars Jul	Sørlandet Hospital Arendal	Norway
<b>Heggheim</b>	Arne	Stavanger University Hospital	Norway
<b>Huang</b>	Ruixia	The Norwegian Radium Hospital	Norway
<b>Hynninen</b>	Johanna	Turku University Hospital	Finland
<b>Høgda11</b>	Claus	Juliane Marie Centret, Rigshospitalet	Denmark
<b>Høgda11</b>	Estrid VS	Herlev Hospital	Denmark



Last name	First name	Affiliation	Country
<b>Høimebakk</b>	Toto	The Norwegian Radium Hospital	Norway
<b>Iversen</b>	Ole Erik	Haukeland University Hospital	Norway
<b>J:son-Söderström</b>	Annelie	Karlskrona Hospital	Sweden
<b>Jeppesen</b>	Ulla	Region Hospital of Randers	Denmark
<b>Jochumsen</b>	Kirsten Marie	Odense University Hospital	Denmark
<b>Jönsson</b>	Jenny-Maria	Skane University Hospital, Lund	Sweden
<b>Kaiander</b>	Christin	Roche Norge	Norway
<b>Karlan</b>	Beth	Cedars-Sinai Medical Center, Los Angeles	USA
<b>Ketabi</b>	Zohreh	Odense University Hospital	Denmark
<b>Kildal</b>	Wanja	The Norwegian Radium Hospital	Norway
<b>Klynning</b>	Charlotte	Karolinska Hospital	Sweden
<b>Komulainen</b>	Marja	Kuopio University Hospital	Finland
<b>Kraggerud</b>	Sigrid Marie	The Norwegian Radium Hospital	Norway
<b>Kristensen</b>	Gunnar	The Norwegian Radium Hospital	Norway
<b>Kristoff</b>	Anne	Stavanger University Hospital	Norway
<b>Kærn</b>	Janne	The Norwegian Radium Hospital	Norway
<b>Langmark</b>	Frøydis	Oslo	Norway
<b>Larsen</b>	Stein	The Norwegian Radium Hospital	Norway
<b>Li</b>	Xiaoran	The Norwegian Radium Hospital	Norway
<b>Lindström</b>	Annika	Centrum för Klinisk Forskning Dalarna	Sweden
<b>Lorenz</b>	Elke	Tønsberg Medical Center	Norway
<b>Lunde</b>	Kristian	Roche Norge	Norway
<b>Mengistu</b>	Meseret	Kvinnohälsan Söder, Stockholm	Sweden
<b>Micci</b>	Francesca	The Norwegian Radium Hospital	Norway
<b>Mikic</b>	Marinko	Sørlandet Hospital Arendal	Norway
<b>Møller</b>	Pål	The Norwegian Radium Hospital	Norway
<b>Nesland</b>	Jahn M	The Norwegian Radium Hospital	Norway
<b>Nilsen</b>	Elisabeth Berge	Stavanger University Hospital	Norway
<b>Noorda</b>	Thomas	Østfold Hospital, Fredrikstad	Norway
<b>Oksefjell</b>	Halldis	Ålesund	Norway
<b>Othman</b>	Suher	North Zealand Hospital	Denmark
<b>Ottosen</b>	Christian	Juliane Marie Centret, Rigshospitalet	Denmark
<b>Persson</b>	Jan	Skane University Hospital, Lund	Sweden
<b>Pradhan</b>	Manohar	The Norwegian Radium Hospital	Norway
<b>Rasmussen</b>	Hege Lund	The Norwegian Radium Hospital	Norway
<b>Riemersma</b>	Cecilia	Karlstad	Sweden
<b>Rintala</b>	Marjut	Turku University Hospital	Finland
<b>Rokkones</b>	Erik	The Norwegian Radium Hospital	Norway
<b>Rokne</b>	Jan Anders	Vestfold Hospital	Norway
<b>Roos</b>	Aviaja Siegstad	Roskilde Hospital	Denmark

<b>Last name</b>	<b>First name</b>	<b>Affiliation</b>	<b>Country</b>
<b>Sachse</b>	Kurt	Akershus University Hospital	Norway
<b>Sahlin</b>	Anna	Kvinnokliniken Eskilstuna	Sweden
<b>Saleem</b>	Zeyad	Halmstad Hospital	Sweden
<b>Sallinen</b>	Hanna Kaisa	Kuopio University Hospital	Finland
<b>Salvesen</b>	Helga	Haukeland University Hospital	Norway
<b>Schnack</b>	Tine Henriksen	Roskilde Hospital	Denmark
<b>Schultz</b>	Janine	Radium Hospital Foundation	Norway
<b>Schulze-Stahl</b>	Niels	Kvinnoklinken Västerås	Sweden
<b>Seppola</b>	Gry	The Norwegian Radium Hospital	Norway
<b>Sert</b>	Bilal	The Norwegian Radium Hospital	Norway
<b>Skeie-Jensen</b>	Tone	The Norwegian Radium Hospital	Norway
<b>Skirnisdottir</b>	Ingridur	Akademiska Hospital, Uppsala	Sweden
<b>Skogsfjord</b>	Karin	The Norwegian Radium Hospital	Norway
<b>Skrøppa</b>	Siri	Vestfold Hospital	Norway
<b>Sletten</b>	Elise	University Hospital of North Norway	Norway
<b>Smebye</b>	Marianne Lislørud	The Norwegian Radium Hospital	Norway
<b>Smehaug</b>	Ola	Roche Norge	Norway
<b>Smogeli</b>	Elisabeth	The Norwegian Radium Hospital	Norway
<b>Solbakken</b>	Ingunn	The Norwegian Radium Hospital	Norway
<b>Solheim</b>	Olesya	The Norwegian Radium Hospital	Norway
<b>Steen</b>	Rita	The Norwegian Radium Hospital	Norway
<b>Steffensen</b>	Karina Dahl	Vejle Hospital	Denmark
<b>Stensager</b>	Per Arne	The Norwegian Radium Hospital	Norway
<b>Sundfeldt</b>	Karin	Sahlgrenska Cancer Centre	Sweden
<b>Sundfør</b>	Kolbein	The Norwegian Radium Hospital	Norway
<b>Szczesny</b>	Witold	Innlandet Hospital	Norway
<b>Søgaard</b>	Charlotte H	Aalborg University Hospital	Denmark
<b>Thranov</b>	Ingrid	Rigshospitalet, Copenhagen	Denmark
<b>Tropé</b>	Ameli	The Norwegian Radium Hospital	Norway
<b>Tropé</b>	Claes	The Norwegian Radium Hospital	Norway
<b>Tveten</b>	Kim Ada	Sobi	Norway
<b>Vistad</b>	Ingvild	Sørlandet Hospital	Norway
<b>Waldstrøm</b>	Marianne	Vejle Hospital	Denmark
<b>Wang</b>	Yun	The Norwegian Radium Hospital	Norway
<b>Wang</b>	Yun Yong	The Norwegian Radium Hospital	Norway
<b>Warsla</b>	Gry	Vestre Viken Hospital Trust	Norway
<b>Woie</b>	Kathrine	Haukeland University Hospital	Norway
<b>Zhong</b>	Yali	The Norwegian Radium Hospital	Norway
<b>Ørtoft</b>	Gitte	Aarhus University Hospital	Denmark

## EGNE NOTATER

[illegible]

## EGNE NOTATER

This image shows a single sheet of white paper with horizontal blue ruling lines. The lines are evenly spaced and run across the width of the page. There are no margins, text, or other markings on the paper.



RADIUM  
HOSPITAL  
FOUNDATION